Close Menu

GSK

This story originally ran on Sept. 14.

Enigma Diagnostics and GlaxoSmithKline said today that they have signed a supply and commercialization agreement for molecular diagnostic tests for use on Engima's fully automated, sample-to-answer real-time PCR system, breathing new life into a partnership begun in 2009.

NEW YORK (GenomeWeb News) – Enigma Diagnostics said today that it has inked a supply and commercialization agreement with GlaxoSmithKline covering its PCR technologies in Europe, India, Brazil, and Russia.

Participating vendors are being asked to build fully functional platforms for next-generation sequence data storage and analysis.

The discovery triggered a milestone payment of an undisclosed amount, Regulus said.

In an analysis of 10 drug companies, pharma consulting firm Diaceutics found that very few of them are prepared to break away from the traditional drug development model and launch personalized medicine products in the next decade.

The company claims Agilent, 454 Life Sciences, Navigenics, Pfizer, and others are infringing on its patent covering a method for analyzing non-coding DNA sequences.

Pages

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.